There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gamida Cell (GMDA – Research Report) and Biophytis (BPTS – Research Report) with bullish sentiments.
Gamida Cell (GMDA)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Gamida Cell, with a price target of $8.00. The company’s shares closed last Tuesday at $1.64.
According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Gamida Cell is a Moderate Buy with an average price target of $6.50, implying a 303.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
Biophytis (BPTS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biophytis, with a price target of $15.00. The company’s shares closed last Tuesday at $3.61, close to its 52-week low of $3.30.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Biophytis is a Moderate Buy with an average price target of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMDA:
